TITAN PHARMACEUTICALS INC (TTNP) Stock Price, Quote, News and Overview
NASDAQ:TTNP - Nasdaq - US8883147055 - Common Stock - Currency: USD
TTNP Quote, Performance and Key Statistics
NASDAQ:TTNP (2/21/2025, 8:00:01 PM)
3.67
-0.14 (-3.67%)
The current stock price of TTNP is 3.67 USD. In the past month the price decreased by -2.78%. In the past year, price decreased by -52.83%.
TTNP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About TTNP
Company Profile
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. The company is headquartered in San Francisco, California and currently employs 4 full-time employees. The firm is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Company Info
TITAN PHARMACEUTICALS INC
Suite 505, 400 Oyster Point Blvd
San Francisco CALIFORNIA 94080 US
CEO: Marc Rubin
Employees: 4
Company Website: https://www.titanpharm.com/
Investor Relations: http://ir.titanpharm.com/
Phone: 14152444990
TITAN PHARMACEUTICALS INC / TTNP FAQ
What is the stock price of TITAN PHARMACEUTICALS INC today?
The current stock price of TTNP is 3.67 USD. The price decreased by -3.67% in the last trading session.
What is the ticker symbol for TITAN PHARMACEUTICALS INC stock?
The exchange symbol of TITAN PHARMACEUTICALS INC is TTNP and it is listed on the Nasdaq exchange.
On which exchange is TTNP stock listed?
TTNP stock is listed on the Nasdaq exchange.
What is TITAN PHARMACEUTICALS INC worth?
TITAN PHARMACEUTICALS INC (TTNP) has a market capitalization of 3.34M USD. This makes TTNP a Nano Cap stock.
How many employees does TITAN PHARMACEUTICALS INC have?
TITAN PHARMACEUTICALS INC (TTNP) currently has 4 employees.
What are the support and resistance levels for TITAN PHARMACEUTICALS INC (TTNP) stock?
TITAN PHARMACEUTICALS INC (TTNP) has a support level at 3.23 and a resistance level at 3.74. Check the full technical report for a detailed analysis of TTNP support and resistance levels.
Should I buy TITAN PHARMACEUTICALS INC (TTNP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TTNP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TTNP, evaluating the profitability, health, valuation and growth aspects
- TITAN PHARMACEUTICALS INC (TTNP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TITAN PHARMACEUTICALS INC (TTNP) Sales and EPS estimates to see what analysts future expectations are.
- TITAN PHARMACEUTICALS INC (TTNP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TITAN PHARMACEUTICALS INC (TTNP) Insider and Institutional Ownership to learn about the owners and their transactions.
- TITAN PHARMACEUTICALS INC (TTNP) Stock Chart to make your own analysis
- TITAN PHARMACEUTICALS INC (TTNP) Latest news and press-releases to stay up to date.
Does TITAN PHARMACEUTICALS INC (TTNP) stock pay dividends?
TTNP does not pay a dividend.
When does TITAN PHARMACEUTICALS INC (TTNP) report earnings?
TITAN PHARMACEUTICALS INC (TTNP) will report earnings on 2025-03-31.
What is the Price/Earnings (PE) ratio of TITAN PHARMACEUTICALS INC (TTNP)?
TITAN PHARMACEUTICALS INC (TTNP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.97).
What is the Short Interest ratio of TITAN PHARMACEUTICALS INC (TTNP) stock?
The outstanding short interest for TITAN PHARMACEUTICALS INC (TTNP) is 4.7% of its float. Check the ownership tab for more information on the TTNP short interest.
TTNP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to TTNP. When comparing the yearly performance of all stocks, TTNP is a bad performer in the overall market: 89.02% of all stocks are doing better.
TTNP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TTNP. The financial health of TTNP is average, but there are quite some concerns on its profitability.
TTNP Financial Highlights
Over the last trailing twelve months TTNP reported a non-GAAP Earnings per Share(EPS) of -6.97. The EPS increased by 15.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -163.41% | ||
| ROE | -182.17% | ||
| Debt/Equity | 0 |
TTNP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to TTNP. The Buy consensus is the average rating of analysts ratings from 6 analysts.